Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018November 12, 2018
Madrigal Pharmaceuticals Reports 2018 Third QuarterNovember 6, 2018
Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical AchievementsAugust 7, 2018
Press Release History
Website Developed by Alan Leff Associates, Inc.